Top

Published in:

01-01-2019 | NSCLC | AdisInsight Report

Lorlatinib: First Global Approval

Author: Yahiya Y. Syed

Published in: Drugs | Issue 1/2019

Abstract

Lorlatinib is an oral small molecule inhibitor of anaplastic lymphoma kinase (ALK) and C-ros oncogene 1 (ROS1) kinase developed by Pfizer for the treatment of ALK-positive non-small cell lung cancer (NSCLC). Based on results from a phase I/II trial, lorlatinib received approval in Japan in September 2018 and in the USA in November 2018 for the treatment of ALK-positive NSCLC. This article summarizes the milestones in the development of lorlatinib leading to the first global approval for this indication.

Zou HY, Li Q, Engstrom LD, et al. PF-06463922 is a potent and selective next-generation ROS1/ALK inhibitor capable of blocking crizotinib-resistant ROS1 mutations. Proc Natl Acad Sci USA. 2015;112(11):3493–8.CrossRef

Basit S, Ashraf Z, Lee K, et al. First macrocyclic 3^rd-generation ALK inhibitor for treatment of ALK/ROS1 cancer: clinical and designing strategy update of lorlatinib. Eur J Med Chem. 2017;134:348–56.CrossRef

Soda M, Choi YL, Enomoto M, et al. Identification of the transforming EML4-ALK fusion gene in non-small-cell lung cancer. Nature. 2007;448(7153):561–6.CrossRef

Solomon B, Wilner KD, Shaw AT. Current status of targeted therapy for anaplastic lymphoma kinase-rearranged non-small cell lung cancer. Clin Pharmacol Ther. 2014;95(1):15–23.CrossRef

Iams WT, Lovly CM. Anaplastic lymphoma kinase as a therapeutic target in non-small cell lung cancer. Cancer J. 2015;21(5):378–82.CrossRef

Shaw AT, Friboulet L, Leshchiner I, et al. Resensitization to crizotinib by the lorlatinib ALK resistance mutation L1198F. N Engl J Med. 2016;374(1):54–61.CrossRef

Pfizer. Lorlatinib (Lorbrena^®): Japanese prescribing Information [English translation]. 2018. https://www.pmda.go.jp. Accessed 26 Nov 2018.

Pfizer. Lorbrena^® (lorlatinib): US rescribing information 2018. https://www.fda.gov. Accessed 26 Nov 2018.

Pfizer. Pfizer's next-generation ALK/ROS1 inhibitor, lorlatinib, granted breakthrough therapy designation from FDA for ALK-positive metastatic non-small cell lung cancer [media release]. http://www.pfizer.com. Accessed 26 Nov 2018.

10.

Pfizer. U.S., EU and Japan health authorities accept regulatory submissions for review of Pfizer’s third-generation ALK inhibitor lorlatinib [media release]. http://www.pfizer.com. Accessed 26 Nov 2018.

11.

Government of Canada. Drug and health product submissions under review (SUR). 2018. https://www.canada.ca. Accessed 20 Nov 2018.

12.

Zou HY, Friboulet L, Kodack DP, et al. PF-06463922, an ALK/ROS1 inhibitor, overcomes resistance to first and second generation ALK inhibitors in preclinical models. Cancer Cell. 2015;28(1):70–81.CrossRef

13.

Guan J, Tucker ER, Wan H, et al. The ALK inhibitor PF-06463922 is effective as a single agent in neuroblastoma driven by expression of ALK and MYCN. Dis Model Mech. 2016;9(9):941–52.CrossRef

14.

Infarinato NR, Park JH, Krytska K, et al. The ALK/ROS1 inhibitor PF-06463922 overcomes primary resistance to crizotinib in ALK-driven neuroblastoma. Cancer Discov. 2016;6(1):96–107.CrossRef

15.

Shaw AT, Felip E, Bauer TM, et al. Lorlatinib in non-small-cell lung cancer with ALK or ROS1 rearrangement: an international, multicentre, open-label, single-arm first-in-man phase 1 trial. Lancet Oncol. 2017;18(12):1590–9.CrossRef

16.

Solomon BJ, Besse B, Bauer TM, et al. Lorlatinib in patients with ALK-positive non-small-cell lung cancer: results from a global phase 2 study. Lancet Oncol. 2018;19(12):1654–67.CrossRef

17.

Ou S, Shaw A, Riely G, et al. Clinical activity of lorlatinib in patients with ROS1+ advanced non-small cell lung cancer: phase 2 study cohort EXP-6 [abstract no. OA02.03 ]. J Thorac Oncol. 2018;13(10 Suppl):S322–S3.

18.

Shaw AT, Martini JF, Besse B, et al. Efficacy of lorlatinib in patients (pts) with advanced ALK-positive non-small cell lung cancer (NSCLC) and ALK kinase domain mutations [abstract no. CT044]. Cancer Res. 2018;78(13 Suppl).

19.

Shaw A, Bauer T, Takahashi T, et al. First-line lorlatinib versus crizotinib for advanced anaplastic lymphoma kinase-positive (ALK⁺) non-small cell lung cancer [abstract no. P1.13-06]. J Thorac Oncol. 2018;13(10 Suppl):S584.

Title: Lorlatinib: First Global Approval
Author: Yahiya Y. Syed
Publication date: 01-01-2019
Publisher: Springer International Publishing
Keywords: NSCLC
Tyrosine Kinase Inhibitors
NSCLC
Tyrosine Kinase Inhibitors
Alectinib
Ceritinib
Crizotinib
Lorlatinib
Published in: Drugs / Issue 1/2019
Print ISSN: 0012-6667
Electronic ISSN: 1179-1950
DOI: https://doi.org/10.1007/s40265-018-1041-0

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lorlatinib: First Global Approval

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 1/2019

Immune Checkpoint Inhibitors in the Treatment of Gastroesophageal Cancer

Current and Emerging Therapies for Non-alcoholic Fatty Liver Disease

Disease-Modifying Therapies in Type 1 Diabetes: A Look into the Future of Diabetes Practice

Targeted Systemic Treatment of Neuroendocrine Tumors: Current Options and Future Perspectives

Emapalumab: First Global Approval

Targeting Angiogenesis in Colorectal Carcinoma